Last reviewed · How we verify
tramacet, naloxone
Tramadol is a centrally acting opioid analgesic that works by binding to opioid receptors in the brain and spinal cord, while naloxone is an opioid antagonist that reverses opioid overdose by blocking opioid receptors.
Tramadol is a centrally acting opioid analgesic that works by binding to opioid receptors in the brain and spinal cord, while naloxone is an opioid antagonist that reverses opioid overdose by blocking opioid receptors. Used for Moderate to moderately severe pain, Opioid overdose reversal.
At a glance
| Generic name | tramacet, naloxone |
|---|---|
| Also known as | tramadol/acetaminophen |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| Drug class | Opioid analgesic |
| Target | Opioid receptors |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
Tramadol's mechanism of action involves the inhibition of the reuptake of norepinephrine and serotonin, as well as the binding to opioid receptors. This results in the analgesic effect. Naloxone, on the other hand, works by competitively binding to opioid receptors, which reverses the effects of opioids and can restore breathing in individuals who have overdosed.
Approved indications
- Moderate to moderately severe pain
- Opioid overdose reversal
Common side effects
- Nausea
- Dizziness
- Vomiting
- Headache
- Constipation
- Itching
- Sedation
- Respiratory depression
Key clinical trials
- Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery (PHASE3)
- The Effect of the Combined Use of Naloxone and Tramacet on Postoperative Analgesia in the Elderly (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: